The Association of Polymorphisms of Secreted Frizzled Related Protein Genes with Circulating Osteoprotegerin (OPG): Soluble Receptor Activator of NF-kB Ligand (sRANKL) and Bone Mineral Density / 대한골다공증학회지

OBJECTIVES: To investigate the relationship between polymorphisms of secreted frizzled related protein (sFRP) genes, circulating osteoprotegerin (OPG), and soluble receptor activator of NF-kB ligand (sRANKL), and bone mineral density (BMD) in postmenopausal Korean women. METHODS: The sFRP1 c.3132C>T, rs16890444, sFRP2 c.-38C>G, and sFRP5 c.20G>C, and c.34A>T polymorphisms were analyzed by Taqman assay and dierect DNA sequencing in 170 postmenopausal Korean women. Serum CrossLaps (CTX), bone alkaline phosphatase (BAP), OPG, and sRANKL were measured by enzyme linked immunosorbent assay. The BMD at the lumbar spine and femoral neck was determined by dual energy X-ray absorptiometry. RESULTS: The sFRP2 c.-38C>G, and sFRP5 c.34A>T polymorphisms were not observed. No significant differences in adjusted BMD of lumbar spine and femoral neck and in risk for osteoporosis were noted among single genotypes of the sFRP genes polymorphisms measured or haplotype genotypes composed of the sFRP1 c.3132C>T and rs16890444 polymorphisms. No statistical significances in serum levels of bone chemical markers except BAP were observed according to single or haplotype genotypes. Serum BAP was significantly higher in women with the GG genotype than those in women with the GC genotype of the sFRP5 c.20G>C polymorphism. CONCLUSIONS: The sFRP1 c.3132C>T, rs16890444 and sFRP5 c.20G>C polymorphisms do not affect BMD at the lumbar spine and femoral neck in postmenopausal Korean women.

The Effects of Estrogen Replacement Therapy and Pamidronate on the Bone Metabolism of Postmenopausal Women / 대한산부인과학회잡지

OBJECTIVE: To evaluate the effects of estrogen replacement therapy and pamidronate on the bone metabolism in the postmenopausal women. METHODS: This prospective randomized clinical trial examined the effects of oral pamidronate and conjugated equine estrogen, in combination and seperately, on biochemical markers of bone turnover in 140 women with low bone mass. Treatment included pamidronate (group I, n=50), or conjugated equine estrogen (group II, n=50), conjugated equine estrogen plus alendronate (group III, n=40) for 12 months. Biochemical markers of bone turnover were also measured at months 6 and 12 months. RESULTS: Serum osteocalcin and urinary deoxypyridinoline in Group I, Group II and Group III decreased signifiantly at 12 months of treatment (p<0.05). But total alkaline phosphatase decreased significantly during the treatment in Group III, but not in Group I and Group II. CONCLUSION: The combined treatment with pamidronate and conjugated equine estrogen is more effective in postmenopausal women with osteoporosis by decreasing bone biochemical markers.